Log in to your Inderes Free account to see all free content on this page.
Novo Nordisk
922.7 DKK +0.4%145 investors are following this company
Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.
Revenue
-
EBIT %
-
P/E
49.42
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
NOVO B
Daily low / high price
921.5 / 926.3
DKK
Market cap
4.12T DKK
Turnover
138.9M DKK
Volume
150K
Financial calendar
Interim report
07.08.2024
Interim report
06.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Novo Holdings AS | 28.3 % | 76.8 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec
Novo Nordisk A/S - share repurchase programme
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio